Drug Type Small molecule drug |
Synonyms MTI-301 |
Target |
Action inhibitors |
Mechanism SCD1 inhibitors(Acyl-CoA desaturase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced cancer | Phase 1 | United States | 09 Apr 2025 | |
Metastatic Solid Tumor | Phase 1 | United States | 09 Apr 2025 | |
Refractory Malignant Solid Neoplasm | Phase 1 | United States | 09 Apr 2025 | |
Unresectable Solid Neoplasm | Phase 1 | United States | 09 Apr 2025 | |
Kidney Neoplasms | Preclinical | United States | 23 Aug 2022 | |
Melanoma | Preclinical | United States | 23 Aug 2022 | |
Triple Negative Breast Cancer | Preclinical | United States | 23 Aug 2022 |